Albert Bourla, Pfizer CEO (John Thys, Pool via AP Images)

How much? Pfiz­er ex­pects to reap at least $26B from Covid vac­cine in 2021

Pfiz­er’s Covid-19 vac­cine is like­ly to bring in about $26 bil­lion in 2021 rev­enues, which is more than $10 bil­lion more than the bio­phar­ma be­he­moth pre­vi­ous­ly pre­dict­ed, the com­pa­ny an­nounced Tues­day morn­ing.

The com­pa­ny said that fig­ure is based on signed con­tracts as of mid-April that amount to 1.6 bil­lion dos­es of the vac­cine to be de­liv­ered this year. And the dra­mat­ic uptick in guid­ance is due to ad­di­tion­al sup­ply agree­ments that have been signed since the com­pa­ny’s pre­vi­ous guid­ance. More may be com­ing too.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.